JP2009532372A5 - - Google Patents

Download PDF

Info

Publication number
JP2009532372A5
JP2009532372A5 JP2009503119A JP2009503119A JP2009532372A5 JP 2009532372 A5 JP2009532372 A5 JP 2009532372A5 JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009503119 A JP2009503119 A JP 2009503119A JP 2009532372 A5 JP2009532372 A5 JP 2009532372A5
Authority
JP
Japan
Prior art keywords
methyl
agent according
hydrogen
agent
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009503119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009532372A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/063288 external-priority patent/WO2007117791A2/en
Publication of JP2009532372A publication Critical patent/JP2009532372A/ja
Publication of JP2009532372A5 publication Critical patent/JP2009532372A5/ja
Pending legal-status Critical Current

Links

JP2009503119A 2006-03-31 2007-03-05 代謝障害の併用治療 Pending JP2009532372A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74402106P 2006-03-31 2006-03-31
PCT/US2007/063288 WO2007117791A2 (en) 2006-03-31 2007-03-05 Combination treatment of metabolic disorders

Publications (2)

Publication Number Publication Date
JP2009532372A JP2009532372A (ja) 2009-09-10
JP2009532372A5 true JP2009532372A5 (https=) 2010-04-22

Family

ID=38581719

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009503119A Pending JP2009532372A (ja) 2006-03-31 2007-03-05 代謝障害の併用治療

Country Status (11)

Country Link
US (1) US8338480B2 (https=)
EP (1) EP2001461A4 (https=)
JP (1) JP2009532372A (https=)
KR (1) KR20080106455A (https=)
CN (1) CN101410105A (https=)
AU (1) AU2007235145B2 (https=)
CA (1) CA2647258A1 (https=)
IL (1) IL194189A0 (https=)
MX (1) MX2008012506A (https=)
NZ (1) NZ571118A (https=)
WO (1) WO2007117791A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101444496B (zh) * 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
CA2602854C (en) 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
US20090176885A1 (en) * 2006-02-02 2009-07-09 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
WO2009033011A1 (en) * 2007-09-07 2009-03-12 Children's Hospital Medical Center Use of secretor, lewis and sialyl antigen levels as predictors for disease
EP2240024A4 (en) * 2008-01-15 2014-05-21 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP2085120A1 (en) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance
UA109638C2 (uk) * 2008-03-13 2015-09-25 Сполуки та спосіб зниження рівня сечової кислоти
ES2651067T3 (es) 2009-07-06 2018-01-24 Children's Hospital Medical Center Inhibición de la inflamación con oligosacáridos de la leche
US20130331452A1 (en) 2010-09-08 2013-12-12 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
US9805725B2 (en) 2012-12-21 2017-10-31 Dolby Laboratories Licensing Corporation Object clustering for rendering object-based audio content based on perceptual criteria
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
JP6553375B2 (ja) * 2014-06-24 2019-07-31 花王株式会社 Ucp−1発現促進剤
WO2015199097A1 (ja) * 2014-06-24 2015-12-30 花王株式会社 Ucp-1発現促進剤
JP6660668B2 (ja) * 2014-06-24 2020-03-11 花王株式会社 Ucp−1発現促進剤
US10758519B2 (en) 2014-06-24 2020-09-01 Kao Corporation UCP-1 expression promoter
EP3288389A4 (en) 2015-04-28 2018-10-10 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0842925A1 (en) 1987-09-04 1998-05-20 Beecham Group Plc Substituted thiazolidinedione derivatives
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
US6172046B1 (en) 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
CZ20033309A3 (cs) 2001-06-07 2004-05-12 Eliálillyáandácompany Modulátory receptorů aktivovaných peroxizomálními proliferátory }PPARB
CN101444496B (zh) 2001-06-12 2011-04-13 维尔斯达医疗公司 用于治疗代谢失调的化合物
EP1556085A4 (en) 2002-11-01 2012-08-22 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM
CN1750758B (zh) * 2003-02-13 2012-06-20 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
RU2358722C2 (ru) 2003-04-15 2009-06-20 Веллстат Терапьютикс Корпорейшн Соединения для лечения метаболических расстройств
US7361686B2 (en) 2003-04-22 2008-04-22 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP4837557B2 (ja) 2003-04-30 2011-12-14 ウェルスタット セラピューティクス コーポレイション 代謝障害の処置のための化合物
EP1656127B1 (en) * 2003-08-20 2011-03-23 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CA2602854C (en) * 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
FR2887881B1 (fr) 2005-07-01 2009-10-09 Pierre Fabre Medicament Sa Inhibiteurs de proteines kinases
WO2007087505A2 (en) 2006-01-25 2007-08-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
JP2009528275A (ja) 2006-01-25 2009-08-06 ウェルスタット セラピューティクス コーポレイション 代謝障害を処置するための化合物

Similar Documents

Publication Publication Date Title
JP2009532372A5 (https=)
JP2022096662A5 (https=)
JP2010501010A5 (https=)
JP2004529174A5 (https=)
AU2007235145B2 (en) Combination treatment of metabolic disorders
US8022063B2 (en) CRTH2 receptor ligands for medicinal uses
JP2023156479A5 (https=)
JP2009531280A5 (https=)
JP2013519680A5 (https=)
JP2010506825A5 (https=)
HRP20140335T1 (hr) Derivati amino-piridina kao agonisti s1p1/edg1-receptora
JP2009528275A5 (https=)
JP2007511485A5 (https=)
JP2010539152A5 (https=)
RU2006142746A (ru) Индолилпроизводные в качестве модуляторов печеночного х-рецептора
JP2019517455A5 (https=)
JP2008513499A5 (https=)
CN1503786A (zh) 高传导率钙-活化k通道开启剂
JP2004509084A5 (https=)
JP2010513397A5 (https=)
CA2513092A1 (en) Compounds for the treatment of metabolic disorders
CN1703407A (zh) 脂肪酸酰胺水解酶抑制剂
CA2607848A1 (en) 3-substituted (3-phenyl)-propionic acid derivatives for the treatment of metabolic disorders
JP2009519965A5 (https=)
TW400330B (en) Novel thiazolidine-2, 4-dione, substitute, the manufacture method and the pharmaceutical compositions therefof